LENSAR, Inc.
LNSR Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 23, 2026
$6.07
KIRA · Stoqly’s AI analyst, in plain words
- LENSAR, Inc. had $58.4M of revenue in fiscal 2025, up 9.2% on the year before. Over five years, revenue changed +17.2% a year on average.
- Its operating margin was −42.1%, down 22.1 pts: of every 100 in sales, about −42 is left after running the business.
- LENSAR, Inc. lost $34.3M in fiscal 2025.
- Free cash flow was −$14.9M in fiscal 2025, −25.5% of revenue.
Market cap
$140M
P/E
—
Revenue
$58.4M
Net income
−$34.3M
Free cash flow
−$14.9M
Operating margin
−42.1%
LENSAR, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+9.2%
Yes. Sales grew 9.2% last year.
Does it make a profit?
−58.7%
No. It lost money last year.
Does profit turn into cash?
−25.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What LENSAR, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Legal name
- LENSAR, Inc.
- CIK
- 0001320350
LENSAR, Inc. · LNSR
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $34.5M | $35.4M | $42.2M | $53.5M | $58.4M |
| Revenue growth | 30.6% | 2.6% | 19.2% | 26.9% | 9.2% |
| Gross margin | 51.8% | 56.4% | 50.1% | 48.3% | 46.4% |
| Operating margin | −57.0% | −57.1% | −29.0% | −19.9% | −42.1% |
| Net income | −$19.6M | −$19.9M | −$14.4M | −$31.4M | −$34.3M |
| Net margin | −56.9% | −56.3% | −34.1% | −58.7% | −58.7% |
| Diluted EPS | −$2.09 | −$1.96 | −$1.31 | −$2.73 | −$2.87 |
| Cash | |||||
| Cash from operations | −$9.0M | −$14.9M | −$9.7M | −$2.3M | −$14.8M |
| Capital expenditure | $0.4M | $0.1M | $0.2M | $0.2M | $0.1M |
| Free cash flow | −$9.3M | −$15.0M | −$9.9M | −$2.4M | −$14.9M |
| FCF margin | −27.1% | −42.3% | −23.5% | −4.5% | −25.5% |
| Share count change | 102.9% | 8.4% | 8.0% | 5.0% | 3.8% |
| Debt and strength | |||||
| Cash and short-term investments | $31.6M | $14.7M | $24.1M | $22.5M | $18.0M |
| Shareholders' equity | $54.9M | $42.0M | $33.4M | $4.9M | −$26.0M |
| Current ratio | 5.1x | 3.0x | 4.0x | 2.8x | 1.2x |
| Returns and quality | |||||
| Return on equity | −32.1% | −41.1% | −38.1% | −164.0% | — |
| Return on tangible equity | −44.5% | −66.7% | −64.2% | — | — |
| Piotroski F-score | 2 | 3 | 3 | 2 | 2 |
| Altman Z'' | 2.7 | −2.3 | −1.6 | −5.4 | −10.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
LENSAR, Inc. · LNSR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $6.07 a share, the company is worth $140M.
Source: SEC EDGAR XBRL filings (CIK 0001320350). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.